Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (COUGH-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04839146
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : April 19, 2021
Sponsor:
Collaborator:
European Union
Information provided by (Responsible Party):
Radboud University

Brief Summary:
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2.

Condition or disease Intervention/treatment Phase
Covid19 Severe Acute Respiratory Syndrome SARS-CoV-2 Infection Biological: ABNCoV2 Vaccine Phase 1

Detailed Description:

This first-in-human phase 1 trial of ABNCoV2 is a single center, sequential dose-escalation, open labelled trial to establish the safety and tolerability of two doses of ABNCoV2, formulated with and without MF59 in healthy, adult, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naïve volunteers. The immunological objective of this trial is to identify a dosage that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2. The trial will be carried out by the Radboud University Medical Center (Radboudumc).

The trial involves first-in-human administration, dose escalation of ABNCoV2 and adjuvant selection. Volunteers will be screened for eligibility and receive two vaccinations by intramuscular injection. While we cannot predict with certainty the safety in human subjects, we have adopted a safety-orientated staggered trial design with ascending doses of ABNCoV2. Seven groups of volunteers (n=6) will receive a given dose of ABNCoV2, either with or without MF59, followed by a booster with the same dose and formulation four weeks after the first vaccination. All vaccinations will be given as intramuscular injection. The pre-defined escalation schedule will start with 6 μg ABNCoV2, with a maximum dose of 70 μg. Dose-escalation will proceed only in absence of protocol-defined safety signals. MF59-adjuvanted and non-adjuvanted formulations will be tested in parallel at the first three escalation steps (Group 1-3) to detect superiority or futility of the MF59-adjuvanted against the non-adjuvanted formulation. Up to forty-two (n=42) subjects will be enrolled, as well as one reserve subject per group.

Safety follow-up will be done at following timepoints: baseline, day 1, day 2, day 7, day 14, day 25, day 29, day 30, day 35, day 42, day 70, day 119 and day 196 after first ABNCoV2 administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: ABNCoV2 is a virus-like particle vaccine. It will be administered as two intramuscular injections in groups of up to 9 volunteers. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination. The pre-defined escalation schedule will start with 6 μg ABNCoV2, followed by 12, 25 and 50 μg with a maximum dose of 70 μg. MF59-adjuvanted and non-adjuvanted formulations will be tested in parallel to detect superiority or futility of the MF59-adjuvanted against the non-adjuvanted formulation at the 6, 12 and 25 μg dosage. Approval for further dose escalation and choice of adjuvant use will be provided by a safety monitoring committee (SMC), supported by pre-defined analyses of safety, tolerability and immunogenicity data at day 14 post-first-vaccination. Recruitment for the two best (safe, tolerable and most immunogenic) regimens will continue until 12 volunteers per regimen have been immunized.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health
Actual Study Start Date : March 11, 2021
Estimated Primary Completion Date : December 20, 2021
Estimated Study Completion Date : December 20, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Experimental: Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant
In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant
In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant
In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant
In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant
In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant
The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2

Experimental: Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant
The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
Biological: ABNCoV2 Vaccine
SARS-CoV-2 vaccine
Other Names:
  • cVLP-RBD
  • RBDn-CLP
  • ABNCoV2




Primary Outcome Measures :
  1. Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE) [ Time Frame: up to 28 weeks ]
    Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE)

  2. Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies [ Time Frame: 14 days following first vaccination. ]
    Concentration of ABNCoV2-specific antibodies


Secondary Outcome Measures :
  1. Secondary study endpoint: Number and severity of at least possibly related solicited AEs [ Time Frame: within one week following administration of ABNCoV2. ]
    Number and severity of at least possibly related solicited AEs


Other Outcome Measures:
  1. Concentration of ABNCoV2-specific antibodies at baseline and during immunization and follow up. [ Time Frame: up to 28 weeks ]
    ABNCoV2-specific antibody concentrations will be measured by ELISA during immunisation and follow-up.

  2. Inhibitory titre in invasion inhibition assay at baseline and during immunization and follow up. [ Time Frame: up to 28 weeks ]
    Inhibitory titres will be measured in an in vitro SARS-CoV-2 invasion inhibition assay.

  3. Cellular immune responses (T and B cell) at baseline and during immunization and follow up. [ Time Frame: up to 28 weeks ]
    Cellular responses will be analysed by cytometry and enzyme-linked absorbent spot (ELISpot) assay.

  4. Correlation of response vaccine to habitual sleep using the Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: one month prior first ABNCoV2 immunization ]
    The PSQI will be used to investigate if sleep quality is associated with immune responses to the vaccine.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject must sign written informed consent to participate in the trial.
  2. Subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). Subjects must score at least 80% correct on a multiple-choice quiz. If they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest.
  3. In the opinion of the investigator, the subject can and will comply with the requirements of the protocol.
  4. Subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study).
  5. Subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of ABNCoV2 administration.
  6. Subject agrees to their general practitioner (GP) being informed about participation in the study and agrees to sign a form to request the release by their GP, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s).
  7. The subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period according to current Sanquin guidelines.
  8. Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. All other female subjects must agree to use continuous adequate contraception2 for the duration of the study. Female subjects must have a negative pregnancy test at the inclusion visit.

Exclusion Criteria:

Any clinically significant abnormal finding on clinical examination or laboratory screening tests according to the US Food and Drug Administration (FDA) Toxicity Grading Scale for Healthy Adult and Adolescent Subjects Enrolled in Preventative Vaccine Clinical Trials [30].

2. History of COVID-19 infection. 3. Chronic use of immunosuppressive drugs or other immune modifying drugs within six months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period.

4. Positive urine toxicology test for cannabis, cocaine or amphetamines at inclusion.

5. Screening tests positive for SARS-CoV-2, SARS-CoV-2 antibodies, Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV).

6. Receipt of any investigational or non-registered product (drug or vaccine) other than the study product in the 30 days preceding enrolment or during the study period.

7. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period.

8. Immunization with any vaccines within the past four weeks or planned receipt of a vaccine during the study period with the exception of a licensed SARS-CoV-2 vaccine, given within the framework of the national SARS-CoV-2 vaccination campaign. The time between last vaccination with ABNCoV2 and a SARS-CoV-2 vaccine provided by the campaign shall be at least 4 weeks.

9. Known hypersensitivity to any of the vaccine components (adjuvant or protein).

10. Administration of immunoglobulins and/or any blood products within the three months prior to the first dose of ABNCoV2 or planned administration during the study period.

11. Previous participation in a COVID-19 vaccine study. 12. Body Mass Index (BMI) >35 kg/m2. 13. Pregnancy, lactation or intention to become pregnant during the study period.

14. History of drug or alcohol abuse interfering with normal functioning in the five years preceding enrolment.

15. Being an employee or student of the department of Medical Microbiology of the Radboudumc, or a person otherwise related to the investigator other than a professional relationship for clinical trial purpose only.

16. Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04839146


Contacts
Layout table for location contacts
Contact: Merel J. Smit, MD 024-3619515 ext +31 merel.smit@radboudumc.nl

Locations
Layout table for location information
Netherlands
Radboud univserity medical center Recruiting
Nijmegen, Gelderland, Netherlands, 6525GA
Contact: Merel J. Smit, MD    024-3619515 ext +31    merel.smit@radboudumc.nl   
Sponsors and Collaborators
Radboud University
European Union
Investigators
Layout table for investigator information
Principal Investigator: Benjamin Mordmüller, Prof Stichting Radboud university medical center
Layout table for additonal information
Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT04839146    
Other Study ID Numbers: NL76192.000.20
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases